Glaxo Wins FDA Approval for Two Targeted Skin Cancer Drugs


Jun 03, 2013

GlaxoSmithKline, the U.K.’s biggest drugmaker, won U.S. approval for two skin cancer drugs targeted at patients most likely to respond to the medications. The Food and Drug Administration approved Tafinlar and Mekinist for patients with melanoma, the most dangerous form of skin cancer, that has spread or can’t be surgically removed. The drugs are aimed at patients who have certain gene mutations that need to be detected using a diagnostic test made by Marcy L’Etoile, France-based BioMerieux (BIM), which the FDA also cleared. Read the full story.
Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments